[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yueyue Li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100618729","registry-for-the-management-of-helicobacter-pylori-infection-in-shandong-province-100618729",false,"NCT07335406","Registry for the Management of Helicobacter Pylori Infection in Shandong Province","Hp-SHAREReg","Inclusion Criteria:\n\n* patients aged 18-80 years, regardless of gender;\n* willing to receive H. pylori eradication therapy;\n* diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C\u002F¹⁴C-urea breath test, or histopathological examination.\n\nExclusion Criteria:\n\n* patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;\n* patients with severe underlying conditions such as hepatic insufficiency, renal insufficiency, or malignant tumours;\n* pregnant or breastfeeding women;\n* individuals who refuse to sign the informed consent form","ALL","18 Years","80 Years",{"count":20,"type":21},10000,"ESTIMATED","1 Year","OBSERVATIONAL","Helicobacter pylori infection is a common global gastrointestinal infectious disease, affecting approximately 43.1% of the world's population. Eradicating H. pylori is crucial for reducing the risk of developing conditions such as gastritis, peptic ulcer disease, and gastric cancer. Currently, 14-day high-dose dual therapy containing amoxicillin and bismuth-containing quadruple therapy are the guideline-recommended first-line treatment regimens for H. pylori eradication. Treatment options for H. pylori vary considerably, with differing efficacy outcomes largely attributable to increasing bacterial antibiotic resistance. Furthermore, multiple factors influence the efficacy of H. pylori eradication, including smoking, body surface area, CYP2C19 gene polymorphisms, patient compliance, and regional variations.\n\nTherefore, to systematically evaluate the efficacy and safety of different treatment regimens alongside the cost-effectiveness of various therapeutic strategies, and to conduct ongoing critical analysis of clinical practice, this study proposes a long-term investigation of real-world clinical practice through a non-interventional cohort study registry. This will assess the effectiveness, safety, and temporal trends of different H. pylori infection treatment regimens, providing real-time evidence to support clinical practice.",[26],"HELICOBACTER PYLORI INFECTIONS",[28],"Helicobacter pylori","RECRUITING","2026-03-27",{"date":32,"type":33},"2026-04-02","ACTUAL",{"date":35,"type":33},"2026-02-01",{"date":37,"type":21},"2035-11-30",{"name":39,"class":40},"Yueyue Li","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100620013","7-day-high-dose-vonoprazan-amoxicillin-dual-therapy-versus-14-day-vonoprazan-amoxicillin-dual-therapy-for-h-pylori-100620013","NCT07352098","7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori","Efficacy and Safety of Short-Term, High-Dose Vonoprazan-Based Dual Therapy Versus Standard-Dose Vonoprazan-Based Dual Therapy for Helicobacter Pylori Eradication: A Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-70 years, no gender restrictions;\n* Patients with H. pylori infection confirmed by 13C\u002F14C-urea breath test ;\n* No prior history of H. pylori eradication therapy;\n\nExclusion Criteria:\n\n* Patients allergic to study medications (vonoprazan fumarate, amoxicillin);\n* Patients with active qastrointestinal bleeding,;\n* Patients undergone or scheduled to undergo surgery within 1 month prior to randomization or during the study period that may affect gastric acid secretion (e.g., gastric surgery, vagotomy, or craniotomy);\n* Patients underlying severe medical conditions deemed by the investigator to potentially confound study results or compromise subject safety, such as: hepatic impairment (ALT or AST \\> 1.5 times the upper limit of normal); renal impairment (Cr ≥ 2.0 mg\u002FdL or eGFR \\\u003C 50 mL\u002Fmin\u002F1.73 m²); immunosuppression; malignancy; severe central nervous system, cardiovascular, or respiratory disease;\n* Patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitors within 2 weeks;\n* Patients with behaviors potentially increasing disease risk: history of chronic substance abuse or alcohol dependence within 12 months prior to screening;\n* Patients planning pregnancy, currently pregnant, breastfeeding, or unwilling to use contraception during the trial period;\n* Patients unable or unwilling to provide informed consent.","70 Years",{"count":51,"type":21},290,"INTERVENTIONAL",[54],"NA","Helicobacter pylori infection is a prevalent global gastrointestinal condition linked to chronic gastritis, peptic ulcer disease, and gastric cancer. Potent and sustained acid suppression improves eradication efficacy. Vonoprazan, a potassium-competitive acid blocker, provides rapid and stable acid inhibition and has become an important component of dual therapy with amoxicillin. However, the optimal dosing strategy and treatment duration for vonoprazan-based dual therapy are not yet fully established.\n\nThis multicenter, open-label, randomized controlled trial compares the efficacy and safety of a short-term, high-dose vonoprazan-based dual therapy (20 mg three times daily for 7 days) with a standard-dose regimen (20 mg twice daily for 14 days), both combined with amoxicillin, for first-line H. pylori eradication. Adult participants with confirmed H. pylori infection will be randomized 1:1 to the two treatment groups. The primary outcome is the eradication rate of H. pylori at 6 weeks after completion of therapy. Secondary outcomes include safety assessments and medication adherence. This study will provide evidence on whether a higher dose and shorter treatment course can achieve similar eradication rates with acceptable safety and tolerability compared to the standard regimen.",[57],"Helicobacter",[59,60],"dual therapy","short term","NOT_YET_RECRUITING","2026-01-11",{"date":64,"type":33},"2026-01-20",{"date":35,"type":21},{"date":67,"type":21},"2028-02-01",{"name":39,"class":40},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":78,"targetDuration":80,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":69},"100614861","p-cabs-based-bismuth-quadruple-therapy-for-helicobacter-pylori-eradication-100614861","NCT07285096","P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication","Efficacy and Safety of P-CABs-Based Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication: A Multicenter Cohort Study","PRO-HP","Inclusion Criteria:\n\n* patients aged 18-70 years, regardless of gender;\n* willing to receive H. pylori eradication therapy;\n* diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C\u002F¹⁴C-urea breath test, or histopathological examination.\n\nExclusion Criteria:\n\n* patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;\n* patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.",{"count":79,"type":21},1730,"8 Weeks","Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.",[83],"Helicobacter Pylori Infection",[28,85],"quadruple therapy","2025-12-20",{"date":88,"type":33},"2025-12-23",{"date":90,"type":33},"2025-12-16",{"date":92,"type":21},"2026-08-01",{"name":39,"class":40},""]